Essential-Biotic® SACCHAROMYCES BOULARDII

Yeast-Based Probiotic for Gastrointestinal and Immune Health*

What It Does
Essential-Biotic Saccharomyces boulardii provides 450 mg (9 billion CFU) of Saccharomyces boulardii per serving which is a non-pathogenic, non-colonizing probiotic yeast that supports gastrointestinal function, microbial balance, and immune health in both adults and children.* It is well tolerated and appropriate for daily use or episodically for digestive support.*

How It Works
• Saccharomyces boulardii: A probiotic yeast that survives stomach acid and does not colonize the human GI tract, making it suitable for short- or long-term supplementation.*[1-3]
• Microbial Interaction: S. boulardii may bind to and neutralize microbial products in the intestinal lumen, supporting healthy bowel motility and microbial balance.*[4-7]
• Biofilm Disruption: Shown in preclinical studies to interact with microbial biofilms, aiding in microbial clearance and mucosal protection.*[8-9]
• Unique Protease Activity: Produces a protease capable of degrading certain microbial toxins and helping restore gut integrity.*[10-11]
• Immune Support: Enhances immune responses by increasing secretory IgA and short-chain fatty acid (SCFA) production, contributing to gut and systemic immune health.*[12-15]
• Well Tolerated: Human trials show efficacy and safety with daily doses ranging from 250 to 1,000 mg in various GI and immune contexts.*[16-26]

Who It’s For
Essential-Biotic Saccharomyces boulardii is ideal for individuals seeking microbial support to support immune and gut barrier function.*

Special Features
Unlike bacterial probiotics, Saccharomyces boulardii does not colonize the gut, making it uniquely positioned to support microbial balance without altering the resident microbiota.* Each capsule contains a research-backed dose for clinical flexibility.*

References
1. McFarland LV. World J Gastroenterol. 2010;16(18):2202–22.
2. Huang R, et al. Transl Pediatr. 2021;10(12):3248–60.
3. Liu LH, et al. BMC Infect Dis. 2023;23(1):878. doi:10.1186/s12879-023-08896-4
4. Martins FS, et al. J Gen Appl Microbiol. 2005;51(2):83–92.
5. Brandao RL, et al. Appl Environ Microbiol. 1998;64:564–8.
6. Vidon N, et al. Gastroenterol Clin Biol. 1986;10:1–4.
7. Ducluzeau R, et al. Ann Microbiol (Paris). 1982;133:491–501.
8. Jawhara S, Poulain D. Med Mycol. 2007;45(8):691–700.
9. Krasowska A, et al. FEMS Yeast Res. 2009;9(8):1312–21.
10. Castagliuolo I, et al. Infect Immun. 1996;64:5225–32.
11. Castagliuolo I, et al. Infect Immun. 1999;67:302–7.
12. Buts JP, et al. Pediatr Res. 2006;60:24–9. doi:10.1203/01.pdr.0000220322.31940.29
13. Vaishnavi C, et al. J Infect Dis. 2008;61(1):1–4.
14. Krause R, et al. Clin Diagn Lab Immunol. 2003;10(1):167–8.
15. Rodrigues AC, et al. J Appl Microbiol. 2000;89(3):404–14.
16. Ozkan TB, et al. J Int Med Res. 2007;35:201–12.
17. Oirard-Pipau F, et al. Microb Ecol Health Dis. 2002;14:220–27.
18. Schneider SM, et al. World J Gastroenterol. 2005;11:6165–9.
19. Kollaritsch H, et al. Travel Med Internatl. 1989;7:9–18.
20. Kollaritsch H, et al. Fortschr Med. 1993;111:152–6.
21. Guslandi M, et al. Eur J Gastroenterol Hepatol. 2003;15(6):697–8.
22. Garcia Vilela E, et al. Scand J Gastroenterol. 2008;43:842–8.
23. Plein K, Hotz J. Z Gastroenterol. 1993;31:129–34.
24. Guslandi M, et al. Dig Dis Sci. 2000;45:1462–4.
25. Surawicz CM, et al. Gastroenterology. 1989;96(4):981–8.
26. McFarland LV. World J Gastroenterol. 2010;16(18):2202–22.